Regulatory and other responses to the pharmaceutical opioid problem

• 1 National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW
• 2 University of Wollongong, Wollongong, NSW
• 3 University of Sydney, Sydney, NSW
• 4 Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, NSW

---

• 1. Campbell G, Lintzeris N, Gisev N, et al. Regulatory and other responses to the pharmaceutical opioid problem. Med J Aust 2019; 210: 6–8. https://www.mja.com.au/journal/2019/210/1/regulatory-and-other-responses-pharmaceutical-opioid-problem
• 2. Ting S, Schug S. The pharmacogenomics of pain management: prospects for personalized medicine. J Pain Res 2016; 9: 49–56.
• 3. Royal College of Pathologists of Australia. Position statement: utilisation of pharmacogenetics in healthcare. Sydney: RCPA, 2018. http://www.rcpa.edu.au/Library/College-Policies/Position-Statements/Utilisation-of-pharmacogenetics-in-healthcare (viewed July 2019).
• 4. Comer SD, Dworkin RH, Strain EC. Medical devices to prevent opioid use disorder: innovative approaches to addressing the opioid crisis. JAMA 2019. https://doi.org/10.1001/jamapsychiatry.2018.4379. [Epub ahead of print]
• 5. Significant decrease in the amount of codeine supplied to Australians — TGA data analysis. Canberra: Therapeutic Goods Administration, 2019. https://www.tga.gov.au/media-release/significant-decrease-amount-codeine-supplied-australians (viewed July 2019).